comparemela.com

Latest Breaking News On - Chief executive officer chris - Page 15 : comparemela.com

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer .

TRADING UPDATES: Ramsens resumes dividend; Watkin Jones profit rises

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.